Avantor (AVTR) Peer Comparison
$16.11
$0.02
(0.12%)
As on 16-Oct-2026 13:43EDT
Market cap
$10,883 Mln
Revenue (TTM)
$6,561 Mln
P/E Ratio
--
P/B Ratio
1.8
Div. Yield
0 %
Edit
| Avantor (AVTR) | Penumbra (PEN) | Repligen (RGEN) | 10X Genomics Inc (TXG) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
10,883 | 12,652 | 11,040 | 10,508 | 9,745 |
Revenue ($ Mln) |
6,561 | 1,505 | 785 | 617 | 2,589 |
Net Profit ($ Mln) |
-578.00 | 160.59 | 41.54 | -75.13 | 222.40 |
Net Margin (%) |
-8.81 | 10.67 | 5.29 | -12.18 | 8.59 |
RoE (%) |
-10.33 | 10.86 | 1.97 | -9.26 | 3.04 |
Price to Earnings |
-- | 78.92 | 238.19 | -- | 46.15 |
Price-To-Book |
1.77 | 8.22 | 4.93 | 11.93 | 1.36 |
Income Statement ($ Mln)
| Avantor (AVTR) | Penumbra (PEN) | Repligen (RGEN) | 10X Genomics Inc (TXG) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Operating Revenue
|
6,561.10 | 1,504.87 | 785.10 | 616.91 | 2,589.30 |
|
Cost of Revenue
|
4,473.00 | 483.98 | 384.30 | 184.88 | 1,245.50 |
|
Gross Profit
|
2,139.40 | 942.44 | 347.62 | 443.88 | 1,343.60 |
|
Operating Expenses
|
2,373.70 | 833.56 | 335.50 | 520.41 | 1,108.90 |
|
Operating Profit (EBIT)
|
-285.60 | 187.34 | 65.30 | -88.38 | 235.00 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
-472.00 | 203.83 | 52.15 | -74.89 | 350.40 |
|
Provision for Tax
|
106.00 | 43.24 | 10.61 | 0.24 | 128.00 |
|
Profit after Tax (Net Income)
|
-578.00 | 160.59 | 41.54 | -75.13 | 222.40 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 93.19 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Avantor (AVTR) | Penumbra (PEN) | Repligen (RGEN) | 10X Genomics Inc (TXG) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
5,630.20 | 1,530.77 | 2,112.03 | 825.55 | 7,173.90 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
4,583.70 | 210.18 | 705.49 | 86.01 | 2,116.80 |
|
Current Liabilities
|
1,382.00 | 233.78 | 132.66 | 118.51 | 961.30 |
|
Total Liabilities
|
11,794.70 | 1,826.52 | 2,949.70 | 1,041.37 | 10,576.50 |
Assets ($ Mln)
| Avantor (AVTR) | Penumbra (PEN) | Repligen (RGEN) | 10X Genomics Inc (TXG) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
9,133.70 | 630.60 | 1,749.63 | 355.40 | 7,231.50 |
|
Current Assets
|
2,462.20 | 1,344.12 | 1,200.55 | 674.67 | 3,020.50 |
|
Total Assets
|
11,794.70 | 1,826.52 | 2,949.70 | 1,041.37 | 10,576.50 |
|
Total Debt*
|
3,697.80 | 212.71 | 690.94 | 78.80 | 1,203.70 |
|
Net Current Assets
|
1,080.20 | 1,110.35 | 1,067.90 | 556.16 | 2,059.20 |
Cashflow ($ Mln)
| Avantor (AVTR) | Penumbra (PEN) | Repligen (RGEN) | 10X Genomics Inc (TXG) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
623.80 | 238.66 | 117.42 | 136.05 | 532.20 |
|
Cash Flow from Investing Activities
|
-130.50 | -404.59 | -298.47 | -13.44 | -189.70 |
|
Cash from Financing Activities
|
-409.40 | 26.53 | -15.21 | 6.80 | -283.20 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Avantor (AVTR) | Penumbra (PEN) | Repligen (RGEN) | 10X Genomics Inc (TXG) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-5.43 | 11.76 | 1.79 | -4.99 | 8.98 |
|
ROE (%)
|
-10.33 | 10.86 | 1.97 | -9.26 | 3.04 |
|
ROA (%)
|
-4.08 | 7.95 | 1.36 | -6.71 | 2.02 |
|
EBIT Margin (%)
|
-4.47 | 13.63 | 9.87 | -1.34 | 15.42 |
|
Net Margin (%)
|
-8.81 | 10.67 | 5.29 | -12.18 | 8.59 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Avantor (AVTR) | Penumbra (PEN) | Repligen (RGEN) | 10X Genomics Inc (TXG) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-1.57 | 17.55 | 16.49 | -4.28 | 1.37 |
|
EBIT Growth (%)
|
-129.16 | 17.49 | 920.91 | 89.59 | -20.02 |
|
Net Profit Growth (%)
|
-184.08 | 8.72 | 400.42 | 11.20 | -30.32 |
|
EPS Growth (%)
|
-184.11 | 8.12 | 394.30 | 16.01 | -29.66 |
|
Book Value Growth (%)
|
-9.82 | 17.33 | 2.16 | 2.26 | 2.19 |
Valuation Ratios
| Avantor (AVTR) | Penumbra (PEN) | Repligen (RGEN) | 10X Genomics Inc (TXG) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-14.68 | 68.93 | 189.42 | -47.60 | -- |
|
Price / Book Value
|
1.77 | 8.22 | 4.40 | 2.60 | -- |
|
Dividend Yield (%)
|
0.00 | 0.00 | -- | -- | -- |
|
EV/EBITDA
|
115.43 | 55.46 | 50.32 | 436.68 | -- |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Avantor (AVTR) | Penumbra (PEN) | Repligen (RGEN) | 10X Genomics Inc (TXG) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.65 | 0.00 | 0.26 | 0.00 | 0.11 |
|
Short term debt to equity ratio
|
0.01 | 0.01 | 0.01 | 0.01 | 0.06 |
|
Current Ratio
|
1.78 | 5.75 | 9.05 | 5.69 | 3.14 |
|
Quick Ratio
|
1.18 | 3.86 | 7.64 | 5.25 | 2.33 |
|
Interest Coverage
|
-1.64 | 157.91 | 1.92 | -24,962.33 | 8.18 |
Operating Efficiency Ratios
| Avantor (AVTR) | Penumbra (PEN) | Repligen (RGEN) | 10X Genomics Inc (TXG) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
17.36 | 12.65 | 20.09 | 8.21 | 17.06 |
|
Asset Turnover
|
0.46 | 0.74 | 0.26 | 0.55 | 0.24 |
|
Receivable days
|
58.79 | 46.54 | 72.41 | 48.40 | 65.39 |
|
Inventory Days
|
64.13 | 331.92 | 146.53 | 128.01 | 221.09 |
|
Payable days
|
58.13 | 26.16 | 29.05 | 23.54 | 37.02 |
|
Cash Conversion Cycle
|
64.79 | 352.30 | 189.88 | 152.87 | 249.46 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
